Lindsay A. Rein, MD, is excited to hear discussions about new data on the treatment of chronic myeloid leukemia (CML) presented at the upcoming 2024 ASH Annual Meeting and Exposition, particularly the recent approval of asciminib for frontline and second-line use, and subsequent efficacy and safety data from the ASC4FIRST and ASC2ESCALATE trials.
Dr Rein is also eager to see data on novel agents like TGRX-678 and HQP1351, which could offer new options for patients who don’t respond to or tolerate current tyrosine kinase inhibitors (TKIs). Combination therapies, as exemplified by the TIPI study of imatinib after ponatinib induction, also hold Dr Rein’s interest, as do managing long-term side effects of CML therapies, particularly cardiovascular risks, and strategies for achieving treatment-free remission. Finally, Dr Rein highlights the need for more research on somatic mutations and defining TKI failure or intolerance to optimize patient care.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2024: Previewing Key Updates and Novel Therapies for Chronic Myeloid Leukemia - Medscape - Dec 02, 2024.
Comments